Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Leukemia, Myeloid trials
The registry lists 12 Leukemia, Myeloid studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 6Phase 2 7Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older PatientsCompletedNCT02845297Phase 2Results posted
- Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
- Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell BehaviorTerminatedNCT01588951Phase 2/3Results posted
- Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood CancersTerminatedNCT00539656Phase 1/2Results posted
- Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
- Red Cell Transfusion Goals in Patients With Acute LeukemiasCompletedNCT02086773Phase 1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative DisordersCompletedNCT00293410Phase 1
- Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00004871Phase 1
- Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00003561Phase 2
- Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00003340Phase 2
- Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00002778Phase 2